Alcohol and Alcoholism Vol. 36, No. 1, pp. 2-10, 2001
© 2001 Medical Council on Alcoholism
INVITED REVIEW
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
Department of Mental Health and Alcohol Research, National Public Health Institute (KTL), FIN-00101, Helsinki, Finland
Received 14 January 2000; )
ABSTRACT
— Eight double-blind placebo-controlled clinical trials in five countries have demonstrated the safety and efficacy of naltrexone as an adjunct in alcoholism treatment. The efficacy depends, however, on how naltrexone is used. Three of the trials tested naltrexone in two ways: (1) with supportive therapy, i.e. support of complete abstinence; (2) with therapy tacitly accepting that relapses may occur and teaching how to cope with them. Although all found benefits from naltrexone with the coping therapy, none of them found any significant benefit of naltrexone over placebo when combined with support for abstinence. These results are consistent with our pre-clinical studies in which naltrexone, naloxone, and nalmefene were effective when paired with drinking but ineffective when given during abstinence. This supported the hypothesis that the primary mechanism involved is extinction (as had been concluded earlier for the effects of naltrexone in opiate addiction treatment), because extinction only weakens responses that are made while reinforcement is blocked. On this basis, it was proposed that: (1) naltrexone should be administered to patients who were still currently drinking; (2) the instructions should be to take naltrexone only when drinking was anticipated; (3) this treatment should continue indefinitely. Subsequently, clinical trials have found that naltrexone used in this manner is safe and effective.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. M. Newton, L. Zeng, V. Wang, J. Connolly, M. J. Wallace, C. Kim, H.-S. Shin, F. Belardetti, T. P. Snutch, and R. O. Messing A Blocker of N- and T-type Voltage-Gated Calcium Channels Attenuates Ethanol-Induced Intoxication, Place Preference, Self-Administration, and Reinstatement J. Neurosci., November 5, 2008; 28(45): 11712 - 11719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Okulicz-Kozaryn, P. Mikolajczak, E. Kaminska, I. Kaminska, M. Szulc, and T. Bobkiewicz-Kozlowska EFFECT OF NALTREXONE ADMINISTRATION ON SHORT-TERM MEMORY IN CHRONICALLY ETHANOL-TREATED OUTBRED RATS Alcohol Alcohol., January 1, 2004; 39(1): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. FRIEDLANDER, S. R. MARDER, J. R. PISEGNA, and J. A. YAGIELA Alcohol abuse and dependence: Psychopathology, medical management and dental implications J Am Dent Assoc, June 1, 2003; 134(6): 731 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zangen, S. Ikemoto, J. E. Zadina, and R. A. Wise Rewarding and Psychomotor Stimulant Effects of Endomorphin-1: Anteroposterior Differences within the Ventral Tegmental Area and Lack of Effect in Nucleus Accumbens J. Neurosci., August 15, 2002; 22(16): 7225 - 7233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rubio, G. Ponce, J. Manzanares, J. D. Sinclair, H. Alho, M. Shinderman, J. H. Krystal, J. A. Cramer, and R. Rosenheck Naltrexone for Alcohol Dependence N. Engl. J. Med., April 25, 2002; 346(17): 1329 - 1331. [Full Text] [PDF]
|
|